Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
70 participants
INTERVENTIONAL
2018-03-13
2019-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility
NCT06481696
Prediction of High Ovarian Response After Assisted Reproductive Techniques
NCT02358421
The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
NCT00867659
Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing In Vitro Fertilisation
NCT01319708
Effect of Different Ovarian Stimulation Protocols on Endometrial Receptivity
NCT03755973
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Resveratrol
Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.
Resveratrol
Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Placebo
Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Control
Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.
Resveratrol
Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Placebo
Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resveratrol
Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Placebo
Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Number of retrieved oocytes greater than 21
Exclusion Criteria
* PCOS
* Endometriosis
* Systemic pathology
* Positive serologies for HBV, HBC and HIV
* Abnormal karyotype
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IVI Madrid
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Juan A Garcia-Velasco
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ivi Madrid
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ortega I, Villanueva JA, Wong DH, Cress AB, Sokalska A, Stanley SD, Duleba AJ. Resveratrol reduces steroidogenesis in rat ovarian theca-interstitial cells: the role of inhibition of Akt/PKB signaling pathway. Endocrinology. 2012 Aug;153(8):4019-29. doi: 10.1210/en.2012-1385. Epub 2012 Jun 19.
Ortega I, Wong DH, Villanueva JA, Cress AB, Sokalska A, Stanley SD, Duleba AJ. Effects of resveratrol on growth and function of rat ovarian granulosa cells. Fertil Steril. 2012 Dec;98(6):1563-73. doi: 10.1016/j.fertnstert.2012.08.004. Epub 2012 Sep 6.
Basini G, Tringali C, Baioni L, Bussolati S, Spatafora C, Grasselli F. Biological effects on granulosa cells of hydroxylated and methylated resveratrol analogues. Mol Nutr Food Res. 2010 Jul;54 Suppl 2:S236-43. doi: 10.1002/mnfr.200900320.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1401-MAD-004-IO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.